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This study investigated the effects of oral administration of pioglitazone (PGT), a specific and 
synthetic ligand of peroxisome proliferator-activated receptors gamma (PPARγ), on follicular 
dynamics and corpus luteum (CL) functionality in dairy cows. Cows exhibiting strong signs of 
estrus after 2 injections of PGF2α (given14 d apart) at d 30 postpartum (n=28) were allotted to 
four groups (n=7 cows/treatment) and orally received 6 mg PGT/kg body weight/day according 
to the following protocol: no PGT (control); PGT for 14 d from 7 d before expected estrus (10 
d after 1st injection of PGF2α) to 7 d after observed estrus (PGT14); PGT for 21 d after observed 
estrus (PGT21); and PGT for 28 d, 7 d before expected estrus to 21 d after observed estrus 
(PGT28). During the first follicular wave, number of follicles (total and small) increased in 
PGT14 and PGT28 cows compared to the control group (P<0.05). During the ovulatory wave, 
number of total and small follicles increased in PGT28 (P<0.05) and PGT21 (P<0.10) 
compared with PGT14 and control cows. Size of the largest follicle at first wave was greater 
in PGT28 (P<0.05), PGT14 (P<0.05) and PGT21 (P<0.10) compared to the control cows. 
Maximal size of the ovulatory follicle was greater in PGT28 (P<0.05) and PGT21 (P<0.10) 
groups compared to the control group. Growth rate of the largest follicle at first wave was 
higher (P<0.05) in PGT-treated cows, while growth rate of the ovulatory wave was higher in 
PGT28 and PGT21 groups, leading to shorter days from luteolysis to ovulation. Pioglitazone 
administration did not affect CL size, but increased progesterone (P4) concentration. The 
PGT14 and PGT28 cows had higher maximal plasma P4 concentration and shorter intervals to 
reach maximal plasma P4 compared to the control group. In conclusion, oral administration of 
PGT had some positive effects on follicular development and circulating P4 levels which may 
be conducive to better reproductive performance. 




Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors 
activated by binding to natural ligands, such as polyunsaturated fatty acids, or synthetic ligands. 
Thiazolidinediones (TZDs), as specific ligands for PPARs, are used in the treatment of type II 
diabetes. The binding of TZDs to their receptors, primarily to PPARγ in adipose cells, increases 
insulin sensitivity (Staels and Fruchart, 2005). A condition of insulin resistance also develops 
during late gestation in high-producing dairy cows and continues into early lactation (Bell, 
1995), which facilitates mobilization of non-esterified fatty acids (NEFA) to mitigate the period 
of negative energy balance, and at the same time decreases the dry matter intake (Drackley, 
1999) with resultant metabolic disorders and low reproductive performance (Bell, 1995; 
Kaneene et al., 1997).  
 The PPARs are widely expressed in tissues such as the ovarian follicles, and CL, and 
exogenous ligands of PPARs may be useful for treating insulin resistance in dairy cows (Smith 
et al., 2007; Schoenberg and Overton, 2011). In vitro studies suggested that PPARs are 
involved in many reproductive processes, including steroidogenesis, folliculogenesis, 
ovulation, fertilization, implantation, and embryo development (Komar et al., 2001; Komar 
and Curry, 2002; Froment et al., 2003; Komar, 2005; Froment et al., 2006).  
Progesterone (P4) secretion from granulosa cells obtained from cows fed with fat-enriched diets 
was increased (Wehrman et al., 1991); an effect that is thought to be related to PPAR activation 
(Singh et al., 2013). Scott et al. (1996) reported that troglitazone (a synthetic PPAR ligand) 
ameliorated the ovulatory function in polycystic ovarian syndrome (POS). The effectiveness 
of PPAR agonists on modulation of in vitro steroidogenesis in rodent granulosa cells was also 
reported (Komar et al., 2001; Froment et al., 2003), mainly through increasing steroidogenic 
enzyme activity and/or speeding up cholesterol transport (Gasic et al., 1998; Froment et al., 
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2003). These findings suggested that natural or synthetic ligands of PPARγ may directly affect 
the ovary. 
Pioglitazone was approved by the USA Food and Drug Administration (FDA) in 1999 and the 
European Medicines Agency (EMA) in 2000 for the treatment of type-II diabetes (Ferwana et 
al., 2013). Administration of PGT for patients with type-II diabetes and in POS women resulted 
in satisfactory outcome (Staels and Fruchart, 2005). People with type-II diabetes are exposed to 
a higher risk of several types of cancer, including a 40% increased risk of bladder cancer, and 
it has been postulated that PGT may increase the risk (Giovannucci et al., 2010). However, 
evidence linking the use of PGT to the increased risk of bladder cancer is controversial. The 
initial findings for a possible association of PGT and bladder cancer originated from a 
preclinical study included in the licensing applications which reported a higher number of 
urothelial hyperplasia in a rat population and malignant tumors in the urinary bladder in the 
animals treated with PGT (Agency, 2011). Nevertheless, subsequent studies revealed that this 
is a rat-specific phenomenon and does not pose a urinary bladder cancer risk to humans (El-
Hage, 2005; Suzuki et al., 2009; Sato et al., 2011). Similarly, in a cohort study of PGT and 
cancer incidence in patients with diabetes, Ferrara et al., (2011) found  no clear evidence of an 
association between use of PGT and risk of the incident cancers examined prostate, pancreas, 
lung/bronchus, colon, non-Hodgkin lymphoma, female breast, endometrial, kidney/renal 
pelvis, rectal, and melanoma. Moreover, recent comprehensive and meta-analysis studies 
reported no connection between long-term use of PGT and the risk of bladder cancer and 
malignancy (Lewis et al., 2015; Filipova et al., 2017). Despite these findings, as described in 
FDA-approved labels, PGT is still contraindicated in patients with active bladder cancer, 
should be used with caution in patients with prior history of bladder cancer, and should not be 
given in patients who develop liver injury (Gourgari et al., 2017).  
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The TZDs reversed the TNFα-induced insulin resistance in steers (Kushibiki et al., 2001), and 
improved dry matter intake, plasma glucose and negative energy balance in transition dairy 
cows (Smith et al., 2007; Smith et al., 2009; Yousefi et al., 2016). A positive effect of TZDs 
on resumption of postpartum ovarian cyclicity was also reported (Smith et al., 2009; Yousefi 
et al., 2016). Dietary supplementation of pioglitazone (PGT), a specific and synthetic ligand of 
PPARγ, improved postpartal ovarian resumption and reproductive performance in transition 
dairy cows (Yousefi et al., 2016). In addition, short-term supplementation of poly-unsaturated 
fatty acids (natural ligands of PPARγ) and TZDs (synthetic ligands of PPARs) effectively 
improved postpartum metabolic condition of dairy cows leading to earlier resumption of 
ovarian cyclicity and improved reproductive performance (Downing and Scaramuzzi, 1991; 
Mattos et al., 2000; Singh et al., 2013; Yousefi et al., 2016). These findings confirmed the in 
vitro studies that reported an increase in PPARγ expression concomitant to the final stage of 
follicular growth and early CL formation (Viergutz et al., 2000; Froment et al., 2003; Komar, 
2005).  
Previous investigations suggested that the improved ovarian activity and reproductive 
performance in TZD-treated transition dairy cows were most likely related to the changes in 
the animal’s metabolism and hormonal profile (Smith et al., 2007; Smith et al., 2009; 
Schoenberg and Overton, 2011; Yousefi et al., 2016).  However, it is not clear whether TZDs 
directly impact on ovarian follicular dynamics and CL function by activating the PPARs in the 
ovarian tissues, or their action on reproduction improvement is limited to metabolism and 
endocrine changes. Therefore, the current study was conducted for better understanding of the 
effect of a TZD ligand on follicular dynamics and CL function in high-producing dairy cows. 
In addition, the optimal time during which the TZD treatment should be applied for the greatest 
impact on follicular dynamics during the pre-estrus, follicular, or luteal phase of the ovarian 
cycle is clarified.  
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 2. Materials and methods 
Under the approval given by Tehran University Ethics Committee, this experiment was 
conducted at the Dairy Farm Research of the Agriculture and Natural Resources College, 
University of Tehran, Iran. 
2.1. Synchronization of the estrous cycle  
Forty Holstein dairy cows (parity 1-3, and 30 days in milk) with no overt signs of disease were 
blocked by BCS and parity, and allocated to four treatment groups (10 cows per group). 
However, only 28 cows (7 cows per group) with strong signs of estrus and ovulation confirmed 
by ultrasonography were used for further observations. Estrous cycles were synchronized by 2 
injections of PGF2α (500 μg Cloprostenol sodium, i.m.; Estroplan, Parnell Technologies PTY. 
LTD., Alexandria, Australia), 14 d apart, started on d 30 postpartum. An average of 3 d was 
considered as withdrawal required for expression of estrual signs following the second PGF2α 
injection. Visual observation of standing estrus was conducted 3 times daily (30-min per 
observation). Ovulation and initiation of the new estrous cycle were confirmed by the absence 
of a largest follicle (diameter ≥ 10 mm) that had been detected at the previous examination 
(ultrasonography test), and subsequent CL formation (Dirandeh, 2014).  
2.2. Experimental design and treatments 
To affect metabolism, at least a 10-14 d administration of TZD ligands is needed (Ghoreishi, 
2012; Yousefi et al., 2016). Cow assignment to treatments was balanced for calculated previous 
305-d mature-equivalent milk yield and BCS. Treatments included: no PGT (control); PGT for 
14 d from 7 d before expected estrus (10 d after 1st injection of PGF2α) to 7 d after observed 
estrus (PGT14); PGT for 21 d after observed estrus (PGT21); and PGT for 28 d; from 7 d 
before expected estrus to 21 d after observed estrus (PGT28), as shown in Fig. 1. A daily dose 
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of 6 mg PGT/kg body weight (BW), in the form of a water suspension, was administered orally 
(at 0800 hour) to PGT cows, and PGT-free water was drenched to the control group. More 
water was then drenched to insure that PGT was completely ingested. 
To adjust PGT level for BW changes during the experiment, the cows were weighed weekly. 
Pioglitazone hydrochloride (Hetero Drugs, India, Batch No. PHD 0510001) was kindly 
provided by Darou Pakhsh Co., Tehran, Iran. Based on ~60% bioavailability of orally 
administered PGT in ruminants (Ghoreishi, 2012; Yousefi et al., 2015; Yousefi et al., 2016) 
and the efficacy of intravenous administration of 2 or 4 mg TZD/kg BW in influencing the 
metabolism and performance of transition cows (Smith et al., 2007; Smith et al., 2009; 
Schoenberg and Overton, 2011), an oral dose of 6 mg PGT/kg BW was chosen. A total mixed 
ration (TMR; Table 1) was fed ad libitum (NRC, 2001). The cows were milked 3 times per day 
at 0700, 1400, and 2300 hours, and milk yield was recorded automatically.  
2.3. Ultrasonography examination 
Ovarian follicular activity was examined daily by transrectal ultrasonography using a real-time 
linear scanning ultrasound diagnostic system (B mode; Piemedical, Falco 100; 8 MHz 
transducer). From one day before expected estrus (d 43 postpartum) to 21 d after observed 
estrus, the ovaries were scanned sequentially. Follicles larger than 3 mm were counted and 
classified as small (< 5 mm), medium (5 to 10 mm), or large (> 10 mm). Horizontal and vertical 
diameters of the follicles and CL were recorded and their averages used in the analysis 
(Dirandeh et al., 2009; Mohammadi et al., 2010). The new follicular wave emergence was 
defined as the day on which the largest follicle was retrospectively first identified as having a 
diameter of 4–5 mm (Dirandeh et al., 2009). The day of luteolysis was defined as the day before 
which serum P4 decreased to less than 50% of the mean for the four maximum P4 concentrations 
in the cycle. Growth rate of the largest follicle was defined as the difference between the 
8 
 
maximal size of the follicle and its size at the first day of the corresponding wave to the period 
needed to reach maximal size. The period of CL activity was calculated from the first day when 
P4 concentration was greater than 1 ng/mL to the day when plasma P4 started to decrease.  
2.4. Blood sampling and P4 assay 
Blood samples were collected from the coccygeal vein in evacuated glass tubes containing 
EDTA (10.5 mg, Monoject; Sherwood Medical, St. Louis, MO, USA) for 21 d, starting on the 
first day of the estrous cycle, at 1-d intervals. Within 1 h of sampling, blood plasma was 
harvested after centrifugation (3000 g, 15 min) and stored at −20°C until analyzed for P4. 
Plasma P4 concentration was measured using a specific ELISA kit (Diaplus Inc., USA), 
following the manufacturer’s instructions. The inter- and intra-assay coefficients of variation 
were 5.3 and 3.4%, respectively. 
2.5. Statistical analysis 
Data on continuous variables such as interovulatory interval, diameter of the ovulatory follicle, 
interval between emergence of last wave and ovulation, growth rate of follicles, days from 
luteolysis to ovulation, maximal size of CL, maximal concentration of plasma P4, days to 
maximal plasma concentration of P4, period of CL activity, and period of CL activity to 
maximal plasma P4 concentration were analyzed by the GLM procedure of statistical analysis 
system software (SAS, 2004). The data measured over time (mean plasma P4 concentrations 
during the estrous cycle, and the number of small, medium, and large follicles) were analyzed 
by the MIXED procedure. Time of sampling (d) was used in the REPEATED statement. The 
model included the fixed effects of treatment, time, interaction between treatment and time, 
and the random effect of cows nested within treatments. The mathematical model was: 
Yijk=µ + Ti + tj + (T × t)ij + δ(T)ik + eijk 
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in which, yijk is the observation on cow k at the sampling time j receiving treatment i; µ is the 
overall mean; Ti is the fixed effect of treatment; tj is the fixed effect of sampling time j (d); 
(T×t)ij is the two-way interaction of treatment i by sampling time j; δ(T)ik is the random effect 
of cow k nested within treatment i, and eijk is the residual random error. Because estrous cycle 
may be affected by the number of the follicular waves, the effect of treatments on the first and 
last waves were analyzed separately. The effects of BW, BCS, level of milk yield, and parity 
measured or assessed at the beginning of the experiment, were used as covariates and/or fixed 
effects; however, they were removed from the model if their effects were not significant, and 
the data reanalyzed subsequently. Means were compared by the Tukey’s test, and results 
expressed as the least squares means and SEM. Statistical significance and tendencies were 
declared at P < 0.05 and 0.05 ≤ P ≤ 0.10, respectively. 
3. Results 
The effects of oral administration of PGT on follicular dynamics are presented in Table 2. 
Pioglitazone administration did not affect the interovulatory interval (P>0.05). During the first 
follicular wave, number of follicles (total and small) increased in PGT14 and PGT28 cows 
compared to the control group (P<0.05). During the ovulatory wave, number of total and small 
follicles increased in PGT28 (P<0.05) and PGT21 (P<0.10) compared with PGT14 and control 
cows. However, treatments did not affect the number of medium and large follicles (P>0.05).  
Size of the largest follicle at first wave was greater in PGT28 (P>0.05) and PGT14 (P>0.05), 
and PGT21 (P<0.10) cows compared to the control group. Maximal size of the ovulatory 
follicle was greater in PGT28 (P<0.05) and PGT21 (P<0.10) groups compared to the control 
group. Growth rate of the largest follicle at first wave was higher (P<0.05) in PGT-treated cows 
compared to control cows, and tended (P<0.01) to be higher in PGT28 than PGT21 group. 
However, growth rate of the ovulatory wave was higher (P<0.05) in PGT28 and PGT21 groups 
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as compared to the control group. Interval between emergence of last wave and ovulation, and 
days from luteolysis to ovulation were decreased (P<0.05) in PGT28 and PGT21 compared to 
the control group (Table 2). 
Table 3 shows the effect of PGT on CL diameter, functionality, and progesterone 
concentration. Maximal CL diameter and period of CL activity were not affected by the 
treatment. Oral administration of PGT increased (P<0.05) mean and maximal concentration of 
P4 in the cows that received PGT from 7 d before the initiation of the cycle (PGT14 and PGT28) 
compared to the control animals. However, mean concentration of plasma P4 tended to increase 
in PGT21 compared to the control group, and in PGT28 compared to PGT21. Administration 
of PGT decreased the number of days to maximal plasma P4 concentration and duration of CL 
activity to maximal plasma P4 concentration in PGT28 and PGT14 compared to the control 
group. However, both PGT14 and PGT28 tended to reach maximal plasma P4 concentration 
sooner than PGT21 group (Table 3). 
At least a 14 d period of PGT administration (7d pre and 7d post estrus) was required to affect 
plasma concentration of P4 (Fig. 2). Following a 14 d period of PGT administration (d 7 of 
cycle), plasma concentration of P4 was significantly increased in PGT14 and PGT28 as 
compared to the control group. The significant difference between PGT28 and the control 
group was maintained up to d 11 of the estrous cycle, but the slope of P4 concentration 
decreased in PGT14 after d 7, resulting in a non-significant difference in P4 concentration 
compared to the control group (Fig. 2). 
 
 
4. Discussion  
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Previous investigations (Smith et al., 2007; Smith et al., 2009; Schoenberg and Overton, 2011; 
Yousefi et al., 2016) on the effect of TZDs administration during the transition period in dairy 
cows reported improvements in the ovarian activity and reproduction, often attributed to the 
systemic effect of TZDs on hormonal or metabolic status (Smith et al., 2007; Smith et al., 
2009). 
In the experiment reported here, greater number of small follicles during first follicular wave 
and increased progesterone concentration were observed in PGT14 and PGT28, but not in 
PGT21 cows. This suggests the importance of pre-estrual supplementation of PGT on 
stimulating the ovarian activity which might have resulted in the recruitment of more first wave 
follicles. This assumption is supported by the higher number of small follicles in PGT28 and 
PGT21, but not in PGT14 cows, during ovulatory wave; where PGT28 and PGT21 cows were 
supplemented with PGT before and during the last follicular wave. Meanwhile, the higher 
number of total follicles observed during the first and last follicular wave may be ascribed to 
the effect of PGT on the number of small follicles. These data are supported by the findings 
that prepartal administration of TZDs enhanced the resumption of ovarian cyclicity in 
postpartum dairy cows (Smith et al., 2009; Yousefi et al., 2016). It has been shown that a period 
of 10-14 d of PGT supplementation is required to modulate metabolism in dairy cows (Arévalo-
Turrubiarte et al., 2012; Ghoreishi, 2012; Yousefi et al., 2016), and PPAR expression is greater 
in small antral follicles (Froment et al., 2003; Singh et al., 2013). Short-term supplementation 
of domestic animals with high energy diets or diets supplemented with polyunsaturated fatty 
acids enhanced the ovarian activity and improved reproductive performance, mainly through 
activation of PPARγ (Downing and Scaramuzzi, 1991; Mattos et al., 2000; Froment et al., 
2006; Singh et al., 2013). In addition, TZDs has been shown to improve insulin sensitively and 
IGF-I production (Smith et al., 2007; Schoenberg and Overton, 2011; Yousefi et al., 2016) 
which are crucial for growth of the ovarian follicles (Kawashima et al., 2007).  
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Greater diameters of the ovulatory follicle and also the largest follicle at first wave in the PGT-
treated groups could be explained by the effect of PPAR ligands on follicular development, 
especially during the final stages of follicular growth (Komar et al., 2001; Komar and Curry, 
2002; Froment et al., 2003; Komar, 2005; Froment et al., 2006). It is worth noting that during 
the first follicular wave, both growth rate and size of large follicles were increased in PGT-
treated cows. However, during the ovulatory wave, growth rate and maximum size of ovulatory 
follicles increased only in PGT28 and PGT21 groups compared with the control and PGT14 
groups. This may be an indication of a close relationship between late-stage follicular growth 
and activation of PPARγ in dairy cows. In agreement with these results, it has been reported 
that administration of natural ligands of PPARs increased the number of follicle, and stimulated 
the growth of preovulatory follicle (Singh et al., 2013). Moreover, PPARγ ligands seem to 
support follicular maturation and CL functionality (Gasic et al., 1998; Viergutz et al., 2000; 
2002; Froment et al., 2003). 
Positive effects of PGT on follicular development, especially the dominant and ovulatory 
follicles, has probably decreased duration of last wave emergence and ovulation, and also in 
the number of days from luteolysis to ovulation, the condition that may lead to maturation of 
an ovulating oocyte with greater fertility potential (Dirandeh et al., 2015). It has been shown 
that a prolonged lifespan of the ovulatory follicle under low circulating P4 results in reduced 
fertility (Mihm et al., 1994). However, it is not clear why PGT supplementation did not affect 
the number of medium and large follicles. Probably, by improving the metabolic and endocrine 
conditions (Smith et al., 2007; Schoenberg and Overton, 2011; Yousefi et al., 2016), PGT 
stimulated follicular recruitment and increased the number of follicles undergoing growth from 
resting pool, and subsequently PGT might affected size of large and preovuratory follicles 
though a direct effect on the receptor, where PPARγ expression in preovulatory follicles 
progressively increases (Komar et al., 2001; Cui et al., 2002; Komar and Curry, 2002; Froment 
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et al., 2003; Komar, 2005; Froment et al., 2006). In addition, the greater growth rate of the 
large follicle at first wave and also ovulatory follicles which caused a greater follicle size during 
a shorter period may increase estradiol production and enhance domination effect of the largest 
follicle on subordinate follicles (Lucy, 2007). This may explain the non-significant effect of 
PGT on the number of medium and large follicle, and also shows that treating cows with PGT 
may not impair the dominance process in dairy cows as an animal with true dominant follicle 
(Mihm and Bleach, 2003; Fortune et al., 2004).   
Higher level of maximum P4 concentration observed at shorter time interval after ovulation 
was probably due to higher efficiency of P4 production under PGT stimulation. Oral 
administration of TZD did not affect the CL size, but plasma P4 levels were 20 to 30% higher 
than in control animals. In this regard, Smith et al. (2009) showed that prepartal administration 
of 2-4 mg of TZD/kg BW did not affect postpartal CL size in dairy cow. Moreover, in 
agreement with this finding, in vitro studies suggested that synthetic PPARγ ligands affected 
the luteal differentiation and functionality rather than cellular proliferation (Komar et al., 2001; 
Froment et al., 2003). It has been widely accepted that there are no direct correlation between 
the size of the CL and circulating P4 (Sartori et al., 2004; De Tarso et al., 2016). However, 
positive effects of TZDs on in vitro hormone synthesis by granulosa (Gasic et al., 1998; 
Froment et al., 2003) or luteal (Lohrke et al., 1998; Schoppee et al., 2002) cells were reported. 
In vitro studies suggested that PPAR enhanced steroidogenesis in rodent granulosa cells 
(Komar et al., 2001; Froment et al., 2003), mainly through increasing the expression and 
activity of the steroidogenic enzymes, and/or speeding up cholesterol transport (Gasic et al., 
1998; Froment et al., 2003), such as cyclooxygenase-2 (Meade et al., 1999), plasminogen 
activator (Xin et al., 1999), or vascular endothelial growth factor (Yamakawa et al., 2000). In 
agreement with the results of the present study, a 1.6-fold increase in P4 production in ovine 
granulosa cells (Froment et al., 2003), and 14-fold increase in P4 and 30% increase in estradiol 
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production by rat granulosa cells (Komar et al., 2001) were reported. However, troglitazone  
inhibited in vitro P4 secretion from the porcine and human granulosa cells (Gasic et al., 1998; 
Froment et al., 2003). These contradictory findings are likely due to species differences, the 
state of differentiation of the granulosa cells, differences between in vitro models, and/or type 
of the PPAR ligands used. 
It is noteworthy that cows receiving PGT from the first day of cycle (PGT21) recorded lower 
plasma concentration of P4 as compared to PGT28 cows that received PGT from 7 d before the 
initiation of the estrous cycle (Table 1). Similar finding was observed in PGT14 during the first 
half of the cycle (Fig. 2). The PPARs are expressed at different stage of the follicular 
development (Cui et al., 2002; Froment et al., 2003; Froment et al., 2006), and their increased 
expression in preovulatory follicles and CL may impact on the functional capacity of the newly 
formed CL (Cui et al., 2002). This hypothesis is supported by the positive effect of PGT 
supplementation on the size of the largest follicles at first wave and ovulatory follicle at last 
waves in the PGT-treated cows. 
In addition to the effects of PGT on ovary which was discussed above, it is worth noting that 
insulin resistance, starting at the prepartum period is continued into early and mid-lactation of 
dairy cows (Chalmeh et al., 2015). The degree of insulin resistance at postpartum period results 
in more net lipolysis from the adipocytes (Chalmeh et al., 2015), and its levels depends on 
several factors such as lactation number, BCS, level of milk yield, and DM intake (Jamali 
Emam Gheise et al., 2017). Although these factors were considered in assigning the animals to 
the treatment groups, and also in the statistical model, direct measuring of insulin resistance 
and application of higher number of cows per group may be conductive to more precise 
interoperation of the treatments’ effect on dependent variables such as P4 level and 
folliculogenesis. Finally, there are several reports published on the effects of TZDs on 
metabolism and reproduction of dairy cows (Kushibiki et al., 2001; Smith et al., 2007; Smith 
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et al., 2009; Schoenberg and Overton, 2011; Ghoreishi, 2012; Singh et al., 2013; Yousefi et al., 
2015; Yousefi et al., 2016; Jamali Emam Gheise et al., 2017); however, no study was conducted 
to figure out the level of TZDs released into the cow's milk.  
 
5. Conclusion 
In conclusion, oral administration of PGT increased the number of small follicles and diameter 
of the largest follicle at the first and ovulatory waves. PGT increased postovulatory plasma P4, 
but decreased duration of the last wave, and days to maximal concentration of plasma P4. 
Pioglitazone treatment at least for 7 d before the initiation of the ovarian cycle had greater 
effect on the ovarian activity and CL functionality. It seems that by activating the PPARγ, PGT 
exerted positive effects on follicular development and CL steroidogenesis. It is implied that at 
least a part of the beneficial effects of TZD on reproductive performance which was reported 
in the previous studies may be due to the direct effects of PPARγ ligands on follicular dynamics 
and CL activity. However, further experiments are required to determine the molecular effects 
of PPARγ ligands on ovarian function and reproduction in dairy cows. 
Acknowledgment 
We acknowledge the financial support of the Iran National Science Foundation [Grant # 
91004246]. MJZ also appreciates the financial support of the Center of Excellence for Studies 
on Reproductive Problems in High-producing Dairy Cows, Shiraz University. 
References 
Agency, E.M., 2011. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact 
(INN: Pioglitazone, pioglitazone+ glimepiride, pioglitazone+ metformin). 
16 
 
Arévalo-Turrubiarte, M., González-Dávalos, L., Yabuta, A., Garza, J., Dávalos, J.L., Mora, O., 
Shimada, A., 2012. Effect of 2, 4-thiazolidinedione on Limousin cattle growth and on 
muscle and adipose tissue metabolism. PPAR Res. 2012. 
Bell, A.W., 1995. Regulation of organic nutrient metabolism during transition from late 
pregnancy to early lactation. J. Anim. Sci. 73, 2804-2819. 
Chalmeh, A., Pourjafar, M., Nazifi, S., Momenifar, F., Mohamadi, M., 2015. Insulin resistance 
in different physiological states of high producing Holstein dairy cows. Acta Sci. Vet. 43. 
Cui, Y., Miyoshi, K., Claudio, E., Siebenlist, U.K., Gonzalez, F.J., Flaws, J., Wagner, K.-U., 
Hennighausen, L., 2002. Loss of the peroxisome proliferation-activated receptor gamma 
(PPARγ) does not affect mammary development and propensity for tumor formation but 
leads to reduced fertility. J. Biol. Chem. 277, 17830-17835. 
De Tarso, S., Apgar, G., Gastal, M., Gastal, E., 2016. Relationships between follicle and corpus 
luteum diameter, blood flow, and progesterone production in beef cows and heifers: 
preliminary results. Anim. Reprod. 13, 81-92. 
Dirandeh, E., 2014. Starting Ovsynch protocol on day 6 of first postpartum estrous cycle 
increased fertility in dairy cows by affecting ovarian response during heat stress. Anim. 
Reprod. 149, 135-140. 
Dirandeh, E., Kohram, H., Shahneh, A., 2009. GnRH injection before artificial insemination 
(AI) alters follicle dynamics in Iranian Holstein cows. Afr. J. Biotechnol. 8, 3672-3676. 
Dirandeh, E., Towhidi, A., Pirsaraei, Z.A., Saberifar, T., Akhlaghi, A., Roodbari, A.R., 2015. 
The endometrial expression of prostaglandin cascade components in lactating dairy cows 
fed different polyunsaturated fatty acids. Theriogenology 83, 206-212. 
17 
 
Downing, J., Scaramuzzi, R., 1991. Nutrient effects on ovulation rate, ovarian function and the 
secretion of gonadotrophic and metabolic hormones in sheep. J. Reprod. Fertil. 43, 209-227. 
Drackley, J.K., 1999. Biology of dairy cows during the transition period: The final frontier? J. 
Dairy Sci. 82, 2259-2273. 
Dunaif, A., Scott, D., Finegood, D., Quintana, B., Whitcomb, R., 1996. The insulin-sensitizing 
agent troglitazone improves metabolic and reproductive abnormalities in the polycystic 
ovary syndrome. J. Clin. Endocrinol. Metab. 81, 3299-3306. 
El-Hage, J., 2005. Peroxisome proliferator-activated receptor agonists: carcinogenicity 
findings and regulatory recommendations. International Athroscleosis Society Symposium 
on PPAR: Monte Carlo, Monaco. 
Ferrara, A., Lewis, J.D., Quesenberry, C.P., Peng, T., Strom, B.L., Van Den Eeden, S.K., 
Ehrlich, S.F., Habel, L.A., 2011. Cohort study of pioglitazone and cancer incidence in 
patients with diabetes. Diabetes Care 34, 923-929. 
Ferwana, M., Firwana, B., Hasan, R., Al‐Mallah, M., Kim, S., Montori, V.M., Murad, M.H., 
2013. Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies. Diabetic 
Med. 30, 1026-1032. 
Filipova, E., Uzunova, K., Kalinov, K., Vekov, T., 2017. Pioglitazone and the risk of bladder 
cancer: a meta-analysis. Diabetes Ther. 8, 705-726. 
Fortune, J., Rivera, G., Yang, M., 2004. Follicular development: the role of the follicular 
microenvironment in selection of the dominant follicle. Anim. Reprod. Sci. 82, 109-126. 
18 
 
Froment, P., Fabre, S., Dupont, J., Pisselet, C., Chesneau, D., Staels, B., Monget, P., 2003. 
Expression and functional role of peroxisome proliferator-activated receptor-γ in ovarian 
folliculogenesis in the sheep. Biol. Reprod. 69, 1665-1674. 
Froment, P., Gizard, F., Defever, D., Staels, B., Dupont, J., Monget, P., 2006. Peroxisome 
proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. 
J. Endocrinol. 189, 199-209. 
Gasic, S., Bodenburg, Y., Nagamani, M., Green, A., Urban, R.J., 1998. Troglitazone Inhibits 
Progesterone Production in Porcine Granulosa Cells 1. Endocrinology 139, 4962-4966. 
Ghoreishi, S.M., 2012. Feeding of pioglitazone in ruminants and its effects on ruminal 
fermentation, some blood parameters, and dry matter intake. Ph.D. Thesis. Isfahan, 
Department of Animal Sciences, Isfahan University of Technology, Isfahan, Iran. 
Giovannucci, E., Harlan, D.M., Archer, M.C., Bergenstal, R.M., Gapstur, S.M., Habel, L.A., 
Pollak, M., Regensteiner, J.G., Yee, D., 2010. Diabetes and cancer: a consensus report. CA. 
Cancer. J. Clin. 60, 207-221. 
Gourgari, E., Wilhelm, E.E., Hassanzadeh, H., Aroda, V.R., Shoulson, I., 2017. A 
comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, 
and emerging cardiovascular safety data. J. Diabetes Complications. 31, 1719-1727. 
Jamali Emam Gheise, N., Riasi, A., Zare Shahneh, A., Celi, P., Ghoreishi, S.M., 2017. Effect 
of pre-calving body condition score and previous lactation on BCS change, blood 
metabolites, oxidative stress and milk production in Holstein dairy cows AU - Jamali Emam 
Gheise, Negin. Ital. J. Anim. Sci. 16, 474-483. 
19 
 
Kaneene, J.B., Miller, R., Herdt, T.H., Gardiner, J.C., 1997. The association of serum 
nonesterified fatty acids and cholesterol, management and feeding practices with peripartum 
disease in dairy cows. Prev. Vet. Med. 31, 59-72. 
Kawashima, C., Fukihara, S., Maeda, M., Kaneko, E., Montoya, C.A., Matsui, M., Shimizu, 
T., Matsunaga, N., Kida, K., Miyake, Y.-I., 2007. Relationship between metabolic hormones 
and ovulation of dominant follicle during the first follicular wave post-partum in high-
producing dairy cows. Reproduction 133, 155-163. 
Komar, C., 2005. Initiation of peroxisome proliferator-activated receptor gamma (PPAR 
gamma) expression in the neonatal rat ovary. Biol. Reprod.: Society for the Study of 
Reproduction 1603 Monroe st, Madison, WI 53711-2021 USA; 2005. p. 183. 
Komar, C.M., Braissant, O., Wahli, W., Curry Jr, T.E., 2001. Expression and localization of 
PPARs in the rat ovary during follicular development and the periovulatory period. 
Endocrinology 142, 4831-4838. 
Komar, C.M., Curry, T.E., 2002. Localization and expression of messenger RNAs for the 
peroxisome proliferator-activated receptors in ovarian tissue from naturally cycling and 
pseudopregnant rats. Biol. Reprod. 66, 1531-1539. 
Kushibiki, S., Hodate, K., Shingu, H., Ueda, Y., Shinoda, M., Mori, Y., Itoh, T., Yokomizo, 
Y., 2001. Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially 
reversed by 2, 4–thiazolidinedione. Domest. Anim. Endocrinol. 21, 25-37. 
Lewis, J.D., Habel, L.A., Quesenberry, C.P., Strom, B.L., Peng, T., Hedderson, M.M., Ehrlich, 
S.F., Mamtani, R., Bilker, W., Vaughn, D.J., 2015. Pioglitazone use and risk of bladder 
cancer and other common cancers in persons with diabetes. Jama 314, 265-277. 
20 
 
Lohrke, B., Viergutz, T., Shahi, S., Pohland, R., Wollenhaupt, K., Goldammer, T., Walzel, H., 
Kanitz, W., 1998. Detection and functional characterisation of the transcription factor 
peroxisome proliferator-activated receptor gamma in lutein cells. J. Endocrinol. 159, 429-
439. 
Lucy, M., 2007. The bovine dominant ovarian follicle. J. Anim. Sci. 85, E89-E99. 
Mattos, R., Staples, C.R., Thatcher, W.W., 2000. Effects of dietary fatty acids on reproduction 
in ruminants. Rev. Reprod. 5, 38-45. 
Meade, E.A., McIntyre, T.M., Zimmerman, G.A., Prescott, S.M., 1999. Peroxisome 
proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. of Biol. Chem. 274, 
8328-8334. 
Mihm, M., Baguisi, A., Boland, M., Roche, J., 1994. Association between the duration of 
dominance of the ovulatory follicle and pregnancy rate in beef heifers. J. of Reprod. Fertil. 
102, 123-130. 
Mihm, M., Bleach, E., 2003. Endocrine regulation of ovarian antral follicle development in 
cattle. Anim. Reprod. Sci. 78, 217-237. 
Mohammadi, G., Kohram, H., Gooraninejad, S., Yousefi, A., Motaghedi, A., 2010. Ovarian 
follicular dynamics during the interovulatory interval in Najdi goats. Afr. J. Biotechnol. 9, 
5236-5239. 
NRC, N.R.C., 2001. Nutrient requirements of dairy cattle. 7th Revised Edition National 
Academy Press, Washington, DC, USA. 
21 
 
Sartori, R., Haughian, J., Shaver, R., Rosa, G., Wiltbank, M., 2004. Comparison of ovarian 
function and circulating steroids in estrous cycles of Holstein heifers and lactating cows. J. 
Dairy Sci. 87, 905-920. 
SAS, 2004. SAS User's Guide Statistics. Cary, NC: SAS Inst., Inc. 
Sato, K., Awasaki, Y., Kandori, H., Tanakamaru, Z.-y., Nagai, H., Baron, D., Yamamoto, M., 
2011. Suppressive effects of acid-forming diet against the tumorigenic potential of 
pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol. Appl. Pharmacol. 
251, 234-244. 
Schoenberg, K., Overton, T., 2011. Effects of plane of nutrition and 2, 4-thiazolidinedione on 
insulin responses and adipose tissue gene expression in dairy cattle during late gestation. J. 
Dairy Sci. 94, 6021-6035. 
Schoppee, P.D., Garmey, J.C., Veldhuis, J.D., 2002. Putative activation of the peroxisome 
proliferator-activated receptor γ impairs androgen and enhances progesterone biosynthesis 
in primary cultures of porcine theca cells. Biol. Reprod. 66, 190-198. 
Singh, D., Sharma, I., Onteru, S.K., 2013. Fuel sensor PPARγ: a potential gateway for fertility 
regulation in buffalo. Buffalo Bull. 32, 204-217. 
Smith, K., Butler, W., Overton, T., 2009. Effects of prepartum 2, 4-thiazolidinedione on 
metabolism and performance in transition dairy cows. J. Dairy Sci. 92, 3623-3633. 
Smith, K., Stebulis, S., Waldron, M., Overton, T., 2007. Prepartum 2, 4-thiazolidinedione alters 
metabolic dynamics and dry matter intake of dairy cows. J. Dairy Sci. 90, 3660-3670. 
Staels, B., Fruchart, J.-C., 2005. Therapeutic roles of peroxisome proliferator–activated 
receptor agonists. Diabetes 54, 2460-2470. 
22 
 
Suzuki, S., Arnold, L.L., Pennington, K.L., Kakiuchi-Kiyota, S., Wei, M., Wanibuchi, H., 
Cohen, S.M., 2009. Effects of pioglitazone, a peroxisome proliferator–activated receptor 
gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 113, 349-357. 
Viergutz, T., Loehrke, B., Poehland, R., Becker, F., Kanitz, W., 2000. Relationship between 
different stages of the corpus luteum and the expression of the peroxisome proliferator-
activated receptor gamma protein in bovine large lutein cells. J. Reprod. Fertil. 118, 153-
161. 
Wehrman, M., Welsh, T., Williams, G., 1991. Diet-induced hyperlipidemia in cattle modifies 
the intrafollicular cholesterol environment, modulates ovarian follicular dynamics, and 
hastens the onset of postpartum luteal activity. Biol. Reprod. 45, 514-522. 
Xin, X., Yang, S., Kowalski, J., Gerritsen, M.E., 1999. Peroxisome proliferator-activated 
receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 
274, 9116-9121. 
Yamakawa, K., Hosoi, M., Koyama, H., Tanaka, S., Fukumoto, S., Morii, H., Nishizawa, Y., 
2000. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial 
growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. 
Commun. 271, 571-574. 
Yousefi, A.R., Kohram, H., Shahneh, A.Z., Zamiri, M.J., Fouladi-Nashta, A.A., 2016. Effects 
of dietary supplementation of pioglitazone on metabolism, milk yield, and reproductive 
performance in transition dairy cows. Theriogenology 85, 1540-1548. 
Yousefi, A.R., Kohram, H., Zare Shahneh, A., Zamiri, M.J., Ghaziani, F., Kazemi Khoozani, 
M., Ghoreishi, S.M., Arab, H.A., 2015. Plasma pharmacokinetics of pioglitazone following 





Fig. 1. An outline of the experimental design indicating initiation of treatment administration 
and duration of pioglitazone (PGT) supplementation. Dairy cows (n=7/group) were not treated 
(control), or orally treated with pioglitazone (6 mg/kg BW per day) for 14 d started from 7 d 
before to 7 d after synchronized estrus (PGT14), or for 21 d after observed estrus (PGT21), or 
for 28 d started from 7 d before expected estrus and continued to 21 d after observed estrus 
(PGT28). Note: Blood samples were collected daily for 21 d, starting on the first day of the 
estrous cycle. Ovaries were scanned daily by transrectal ultrasonography from one day before 






Fig. 2. Effect of daily oral administration of pioglitazone (6 mg/kg BW per day) on plasma 
concentration of progesterone during the estrous cycle (n=7 cows/group). Details of the 
treatments are given in Fig. 1. Different letters (a,b) within the each week indicate significant 
differences P < 0.05. Note: P values for the effects of treatment, time, and interaction between 




Table 1. Ingredients and chemical composition of the experimental diet 
Dietary ingredients  % DM 
Alfalfa hay (mid-bloom) 20.25 
Corn silage (10% grain) 18.28 
Ground barley grain 19.73 
Ground corn grain  3.46 
Beet pulp  5.75 
Soybean meal  7.96 
Canola meal 7.27 
Corn gluten meal 1.73 
Meat meal 1.73 
Cottonseed, whole 2.94 
Wheat grain 2.94 
Fish meal 1.11 
Megalac (rumen protected fat) 1.73 
Wheat bran 0.24 
Vitamin and mineral premixa 0.76 
Sodium bicarbonate  1.00 
Salt 0.24 
Limestone 0.48 
Dicalcium phosphate 0.35 
Zeolite 1.73 
Biotin supplement 0.09 
MycoSorbb 0.07 
Magnesium oxide 0.17 
Diet composition  
DM, % 59 
NEL (Mcal/kg DM) 1.63 
CP, % 18.5 
ADF, % 18 
NDF, % 30 
NFC, % 35 
Calcium, % 1.31 
Phosphorus, % 0.63 
a Contained (per kg): 16,000,000 IU vitamin A; 3,200,000 IU vitamin D; 48,000 IU vitamin 
E; 24.0 g Mn; 24.0 g Zn; 24.0 g Fe; 12.8 g Cu; 1.44 g I; 0.32 g Se; and 0.32 g Co. 
b Mycotoxin binder, contained: 95% silicates (calcium silicate, sodium and aluminum silicate, 




Table 2. Least squares means for the effect of oral administration of pioglitazone (6 mg PGT/kg 
BW per day) on follicular dynamics in Holstein dairy cows (n=7 per treatmenta) 
Item Control PGT14 PGT21 PGT28 SEM 
Interovulatory interval (d) 22.28 22.14 21.57 21.45 0.50 
First wave 
     
Number of small follicles (< 5 mm) 8.62b,B 10.90a,A 8.90ab,B 11.13a,A 0.86 
Number of medium follicles (5-10 mm) 3.46 4.59 4.61 3.41 0.58 
Number of large follicles (>10 mm) 0.67 0.97 0.96 1.14 0.25 
Total number of follicles  12.78b 16.64a 14.42ab 15.60a 1.11 
Size of the largest follicle (mm) 11.43b,B 14.03a,A 13.28ab,A 14.71a,A 0.56 
Growth rate of the largest follicle (mm/d) 0.92b,C 1.45a,AB 1.27a,BC 1.56a,A 0.09 
Ovulatory wave 
     
Number of small follicles (< 5 mm) 8.21b,C 8.87b,BC 10.53ab,A 11.79a,A 1.04 
Number of medium follicles (5-10 mm) 3.19 3.70 4.90 3.65 0.51 
Number of large follicles (>10 mm) 0.68 0.80 0.63 0.91 0.14 
Total number of follicles  13.01b 13.20b 16.33a 16.18a 1.08 
Maximal size of ovulatory follicle (mm) 14.58b,B 15.02b,B 16.85ab,A 17.71a,A 0.52 
Growth rate of ovulatory follicle (mm/d) 1.21b 1.28b 1.67a 1.78a 0.10 
Interval from last wave to ovulation (d) 11.42a 10.68ab 9.91b 9.80b 0.40 
Days from luteolysis to ovulation 5.71a 5.01ab 4.14b 4.50b 0.29 
Different letters (a, b) within the same row indicate significant differences P < 0.05. 
Different letters (A–C) within the same row indicate significant differences P < 0.10. 
BW = body weight; SEM = standard error of mean. 
a Details of the treatments are given in Fig. 1. 
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Table 3. Least squares means for the effect of oral administration of pioglitazone (6 mg PGT/kg 
BW per day) on corpus luteum (CL) diameter and circulating progesterone levels in Holstein 
dairy cows (n=7 per treatmenta) 
Item PGT0 PGT14 PGT21 PGT28 SEM 
Maximum diameter of CL (mm) 17.05 19.50 17.42 20.21 2.02 
Period of CL activity (d)  14.42 14.28 14.91 14.75 0.46 
Mean plasma P4 concentration (ng/mL) 3.01
c,C 3.80ab,AB 3.59bc,B 4.29a,A 0.17 
Maximum concentration of plasma P4 (ng/mL) 7.07
b 7.99a 7.35ab 9.04a 0.60 
Days to maximal concentration of plasma P4 (d)  13.57
a,A 11.28b,B 13.28ab,A 11.04b,B 0. 58 
Period of CL activity to maximal plasma P4 
concentration (d) 
10.57a,A 8.10b,B 10.28ab,A 8.03b,B 0.86 
Different letters (a,b) within the same row indicate significant differences P < 0.05. 
Different letters (A–C) within the same row indicate significant differences P < 0.10. 
BW = body weight; SEM = standard error of mean. 
a Details of the treatments are given in Fig. 1. 
 
 
